Senseonics Holdings, Inc. (NASDAQ: SENS) has begun an underwritten public offering of common stock and pre‑funded warrants with a target size of $80 million. The proceeds are intended to provide working capital and support the launch of its Eversense 365 implantable continuous glucose monitor in new markets, as well as ongoing pipeline development.
The offering follows the company’s transition to full commercial responsibility for the Eversense 365, which has increased operating expenses. Senseonics’ 2026 financial outlook projects operating expenses of $150 million to $160 million, reflecting the integration of the commercial organization and product launches. The $70 million increase in operating expenses for 2026 aligns with the projected overall expense level.
The company’s cash position as of December 31 2025 was $94.3 million, with $35.3 million in outstanding indebtedness. The expanded $100 million Hercules credit facility provides access to about $65 million of non‑dilutive capital, helping to offset the stepped‑up operating expenses and avoid covenant breaches.
The $80 million equity raise, combined with the Hercules facility, is expected to strengthen Senseonics’ liquidity and support the company’s growth strategy. The capital will fund the European launch of the Eversense 365, which recently received CE Mark approval, and further investment in the company’s pipeline, including the Gemini sensor trial slated for completion in the second half of 2026.
Management highlighted the commercial expansion as a key growth driver. CEO Tim Goodnow noted that the European launch “is a significant breakthrough for diabetes technology in Europe and for Senseonics as a business, as we successfully transition to an end‑to‑end commercial organization this year.” CFO Frederick Sullivan added that the company expects full‑year 2026 global net revenue of $58 million to $62 million, representing a 65% to 76% year‑over‑year increase from 2025.
The offering is a material event that will alter Senseonics’ capital structure and result in shareholder dilution. The company’s prior quarter results showed a net loss of $20.8 million in Q4 2025, up from $15.5 million in Q4 2024, and total revenue of $14.3 million, a 72% increase from $8.3 million in Q4 2024. The new financing is intended to sustain the company’s cash burn of $110 million to $120 million projected for 2026.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.